Sequencing hormonal ablation and radiotherapy in prostate cancer: A molecular and therapeutic prespective (Review)

Oncology Reports

Volumn 9, Issue 6, 2002, Pages 1151-1156

  Hill, Brian ^a   Kyprianou, Natasha ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Androgen ablation; Apoptosis; bcl 2; Prostate cancer; Radiotherapy

Indexed keywords

ANTIANDROGEN;

APOPTOSIS; DRUG RESISTANCE; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATE TUMOR; REVIEW;

ANDROGEN ANTAGONISTS; APOPTOSIS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0036835534     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.6.1151     Document Type: Review

References (64)

1. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics. CA Cancer J Clin 50: 7-33, 2000.
2. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT and Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277: 1445-1451, 1997. (Pubitemid 27208886)
3. Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt JT and Zincke H: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 156: 137-143, 1996. (Pubitemid 26185656)
4. Roach M III: Current status of androgen suppression and radiotherapy for patients with prostate cancer. J Steroid Biochem Mol Biol 69: 239-245, 1999.
5. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA and Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989. (Pubitemid 19211484)
6. Bruckheimer EM and Kyprianou N: Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res 301: 153-162, 2000. (Pubitemid 30459862)
7. Isaacs JT: The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 26: 263-273, 1999.
8. Rudin CM and Thompson CB: Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med 48: 267-281, 1997. (Pubitemid 27101830)
9. Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science 281: 1305-1308, 1998. (Pubitemid 28406815)
10. Deveraux QL, Roy N, Stennicke HR, Va Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS and Reed JC: IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17: 2215-2223, 1996. (Pubitemid 28171907)
11. Kimura K, Markowski M, Bowen C and Gelmann EP: Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res 61: 5611-5618, 2001. (Pubitemid 32700276)
12. Massague J: The transforming growth factor-beta family. Annu Rev Cell Biol 6: 597-641, 1990.
13. Martikainen P, Kyprianou N and Isaacs JT: Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology 127: 2963-2968, 1990.
14. Guo Y and Kyprianou N: Restoration of TGF-β signaling pathway suppresses tumorigenicity of human prostate cancer cells via induction of caspase-1 mediated apoptosis. Cancer Res 59: 1366-1371, 1999. (Pubitemid 29136271)
15. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
16. Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991. (Pubitemid 21896613)
17. Vogelstein B and Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
18. Kyprianou N and Rock S: Radiation-induced apoptosis of human prostate cancer cells is independent of mutant p53 overexpression. Anticancer Res 18: 897-906, 1998.
19. Lee JM and Bernstein A: p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sei USA 90: 5742-5746, 1993. (Pubitemid 23176238)
20. Shi X-B, Nesslinger NJ, Deitch AD, Gumerlock PH and De Vere White RW: Complex functions of mutant p53 alleles from human prostate cancer. Prostate 51: 59-72, 2002. (Pubitemid 34274861)
21. Berges RR, Vukanovic J, Epstein JI, Car Michel M, Cisek L, Johnson DE, Veltri RW, Walsh PC and Isaacs JT: Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1: 473-480, 1995.
22. Tu H, Jacobs SC, Borkowski A and Kyprianou N: Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-betal and bcl-2 expression. Int J Cancer 69: 357-363, 1996. (Pubitemid 26384103)
23. Huggins C and Hodges CV: Studies on prostatic cancer. Effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297, 1941.
24. Kyprianou N and Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122: 552-562, 1988. (Pubitemid 18060946)
25. Kyprianou N, English HF and Isaacs JT: Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50: 3748-3753, 1990. (Pubitemid 20194126)
26. Blasko JC and Cavanagh W: A comparison of different irradiation therapies for prostate cancer. Monogr Urol 125: 18023, 1997.
27. Ramos CG, Carvalhal GF and Smith DS: Retrospective comparison of radical prostatectomy and 125I- iodine brachytherapy for localized prostate cancer. J Urol 161: 1212-1218, 1999.
28. Rupnow BA, Murtha AD, Alarcon RM, Giaccia AJ and Knox SJ: Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res 58: 1779-1784, 1998. (Pubitemid 28217445)
29. Brown JM and Wouters BG: Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59: 1391-1399, 1999. (Pubitemid 29160097)
30. Yu Y and Little JB: p53 is involved in but not required for ionizing radiation-induced caspase-3 activation and apoptosis in human lymphoblast cell lines. Cancer Res 58: 4277-4281, 1998. (Pubitemid 28450025)
31. Colletier PJ, Ashoori F, Cowen D, Meyn RE, Tofilon P, Meistrich ME and Pollack A: Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. Int J Radiat Oncol Biol Phys 48: 1507-1512, 2000.
32. Sasaki R, Shirakawa T, Zhang ZJ, Tamekane A, Matsumoto A, Sugimura K, Matsuo M, Kamidono S and Gotoh A: Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int J Radiat Oncol Biol Phys 51: 1336-1345, 2001. (Pubitemid 33116329)
33. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886, 1992.
34. Kyprianou N, King ED, Bradbury D and Rhee JG: Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 70: 341-348, 1997. (Pubitemid 27099605)
35. Huang A, Gandour-Edwards R, Rosenthal SA, Siders DB, Deitch AD and White RW: p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 51: 346-351, 1998. (Pubitemid 28093197)
36. Grossfeld GD, Olumi AF, Connolly JA, Chew K, Gibney J, Bhargava V, Waldman FM and Carroll PR: Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol 159: 1437-1443, 1998. (Pubitemid 29117316)
37. Scherr DS, Vaughan ED Jr, Wei J, Chung M, Felsen D, Allbright R and Knudsen BS: Bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 162: 12-17, 1999. (Pubitemid 29420869)
38. Szostak MJ, Kaur P, Amin P, Jacobs SC and Kyprianou N: Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol 165: 2126-2130, 2001.
39. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994. (Pubitemid 24163411)
40. Mackey TJ, Borkowski A, Amin P, Jacobs SC and Kyprianou N: Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52: 1085-1090, 1998. (Pubitemid 28533381)
41. Laverdiere J, Gomez JL, Cusan L, Suburu ER, Diamond P, Lemay M, Candas B, Fortin A and Labrie F: Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37: 247-252, 1997. (Pubitemid 27138705)
42. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT and Pilepich MV: Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49: 937-946, 2001. (Pubitemid 32184600)
43. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M and Grignon D: Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50: 1243-1252, 2001. (Pubitemid 32727802)
44. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L and Pierart M: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295-300, 1997. (Pubitemid 27318990)
45. Whittington R, Malkowicz SB, Machtay M, van Arsdalen K, Barnes MM, Broderick GA and Wein AJ: The use of combined radiation therapy and hormonal therapy in the management of lymph node-positive prostate cancer. Int J Radiat Oncol Biol Phys 39: 673-680, 1997. (Pubitemid 27441436)
46. Buskirk SJ, Pisansky TM, Atkinson EJ, Schild SE, O'Brien PC, Wolfe JT and Zincke H: Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy. Mayo Clin Proc 76: 702-706, 2001. (Pubitemid 32600069)
47. Zagars GK, Pollack A and von Eschenbach AC: Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 58: 233-239, 2001. (Pubitemid 32728063)
48. Roach M III: Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer. Eur J Urol 32: 48-54, 1997.
49. Spry NA, Meffan PM, Christie DR and Morum PE: Ordhidectomy prior to definitive radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 34: 1045-1053, 1996. (Pubitemid 26105442)
50. Whittington R, Broderick GA, Arger P, Malkowicz SB, Epperson RD, Arjomandy B and Kassaee A: The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 44: 1107-1110, 1999. (Pubitemid 29342912)
51. Zelefsky MJ and Harrison A: Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 49: 38-45, 1997. (Pubitemid 27133509)
52. Joon DL, Hasegawa M, Sikes C, Khoo VS, Terry NH, Zagars GK, Meistrich ML and Pollack A: Supra additive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 38: 1071-1077, 1997. (Pubitemid 27353688)
53. Pollack A, Joon DL, Wu CS, Sikes C, Hasegawa M, Terry NH, White RA, Zagars GK and Meistrich ML: Quiescence in R3327-G rat prostate tumors after androgen ablation. Cancer Res 57: 2493-2500, 1997. (Pubitemid 27255912)
54. Garzotto M: Combined androgen deprivation with radiotherapy for prostate cancer: does it make sense? Mol Urol 4: 209-215, 2000.
55. Bruckheimer EM and Kyprianou N: Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology 142: 2419-2426, 2001. (Pubitemid 32473098)
56. Randall K and Coggle JE: Long-term expression of transforming growth factor TGF-beta1 in mouse skin after localized irradiation. Int J Radiat Biol 70: 351-360, 1996. (Pubitemid 26294842)
57. Garzotto M, Haimovitz-Friedman A, Liao WC, White-Jones M, Huryk R, Heston WD, Cordon-Cardo C, Kolesnick R and Fuks Z: Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res 59: 5194-5201, 1999. (Pubitemid 29503982)
58. Winter RN, Rhee J and Kyprianou N: Caspase-1 restoration enhances the apoptotic response of prostate cancer cells to ionizing radiation. Cell Death Different (In press).
59. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG and Pehamberger H: Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4: 232-234, 1998. (Pubitemid 28137379)
60. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, Di Stefano F and Cotter FE: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18: 1812-1823, 2000. (Pubitemid 30261918)
61. Nicholson DW: From bench to clinic with apoptosis-based therapeutic agents. Nature 407: 810-816, 2000.
62. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E and Goldie J: Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 5: 2891-2898, 1999. (Pubitemid 29493968)
63. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, De Forge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
64. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999. (Pubitemid 29068521)